Abstract
DESPITE tremendous efforts in the search for safe, efficacious and non-addictive opioids for pain treatment, morphine remains the most valuable painkiller in contemporary medicine. Opioids exert their pharmacological actions through three opioid-receptor classes1,2, µ, δ and κ, whose genes have been cloned3. Genetic approaches are now available to delineate the contribution of each receptor in opioid function in vivo. Here we disrupt the μ-opioid-receptor gene in mice by homologous recombination and find that there are no overt behavioural abnormalities or major compensatory changes within the opioid system in these animals. Investigation of the behavioural effects of morphine reveals that a lack of μ receptors abolishes the analgesic effect of morphine, as well as place-preference activity and physical dependence. We observed no behavioural responses related to δ- or κ-receptor activation with morphine, although these receptors are present and bind opioid ligands. We conclude that the µ-opioid-receptor gene product is the molecular target of morphine in vivo and that it is a mandatory component of the opioid system for morphine action.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Browstein, M. Proc. Natl Acad. Sci. USA 90, 5391–5393 (1993).
Goldstein, A. & Naidu, A. Mol. Pharmacol. 36, 265–272 (1989).
Kieffer, B. L. Cell. Mol. Neurobiol. 15, 615–635 (1995).
Pasternak, G. W. Clin. Pharmacol. 16, 1–18 (1993).
Rossier, J. Nature 298, 221–222 (1982).
Cowan, A. in Handbook of Experimental Pharmacology Opioids II (ed. Herz, A.) Vol. 104, 393–414 (Springer, Berlin, 1993).
Roques, B. P., Noble, F., Daugé, V., Fournié-Zaluski, M.-C. & Beaumont, A. Pharmacol. Rev. 45, 87–146 (1993).
Baamonde, A., Daugé, V., Gacel, C. & Roques, B. P. J. Pharmacol. Exp. Ther. 257, 767–773 (1991).
Dickenson, A. H. Br. Med. Bull. 47, 690–702 (1991).
Gacel, G., Zajac, J. M., Delay-Goyet, P., Dauge, V. & Roques, B. P. J. Med. Chem. 31, 374–383 (1988).
Di Chiara, G. & North, A. Trends Pharmacol. Sci. 13, 185–193 (1992).
Koob, G. F. Trends Biochem. Sci. 13, 177–184 (1992).
Katz, R. J. & Gormezano, G. Pharmacol. Biochem. Behav. 11, 231–233 (1979).
Shippenberg, T. S., Bals-Kubik, R. & Herz, A. Brain Res. 436, 234–239 (1987).
Terwillinger, R. Z., Beitner-Johnson, D., Sevarino, K. A., Crain, S. M. & Nestler, E. J. Brain Res. 548, 100–110 (1991).
Maldonado, R., Negus, S. & Koob, G. F. Neuropharmacology 31, 1231–1241 (1992).
Wei, E. T. J. Pharmacol. Exp. Ther. 216, 12–18 (1981).
Cowan, A., Zhu, X. Z., Mosberg, H. I., Omnaas, J. R. & Porreca, F. J. Pharmacol. Exp. Ther. 246, 950–955 (1988).
Traynor, J. R. & Elliot, J. Trends Pharmacol. Sci. 14, 84–85 (1993).
Kieffer, B. L., Befort, K., Gavéeriaux-Ruff, R. C. & Hirth, C. G. Proc. Natl Acad. Sci USA 89, 12048–12052 (1992).
McBurney, M. W. et al. Nucleic Acids Res. 19, 5755–5761 (1991).
Lufkin, T., Dierich, A., LeMeur, M., Mark, M. & Chambon, P. Cell 88, 1105–1119 (1991).
Ilien, B. et al. Biochem. Pharmacol. 37, 3843–3851 (1988).
Kitchen, I. et al. J. Pharmacol. Exp. Ther. 275, 1595–1607 (1995).
Décimo, D., Labouesse, G. & Dollé, P. in Gene probes 2: A Practical Approach (eds Names, B. D. & Higgins, S.) 183–210 (Oxford Univ. Press, 1995).
Schmidt, C. et al. Eur. J. Pharmacol. 192, 253–262 (1991).
Valverde, O., Fournier-Zaluski, M.-C., Roques, B. P. & Maldonado, R. Psychopharmacology 123, 119–126 (1996).
Maldonado, R. et al. Science 273, 657–650 (1996).
Hanoune, J., Stengel, D., Lacombe, M. L., Fledmann, G. & Coudrier, E. J. Biol. Chem. 252, 2039–2045 (1977).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Matthes, H., Maldonado, R., Simonin, F. et al. Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the µ-opioid-receptor gene. Nature 383, 819–823 (1996). https://doi.org/10.1038/383819a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/383819a0
This article is cited by
-
Genetic mouse models in opioid research: current status and future directions
Journal of Neural Transmission (2024)
-
Ventral tegmental area glutamate neurons establish a mu-opioid receptor gated circuit to mesolimbic dopamine neurons and regulate opioid-seeking behavior
Neuropsychopharmacology (2023)
-
Red hair and pain sensitivity: insights into genomics of pain?
Anesthesiology and Perioperative Science (2023)
-
Targeting Peripheral μ-opioid Receptors or μ-opioid Receptor-Expressing Neurons Does not Prevent Morphine-induced Mechanical Allodynia and Anti-allodynic Tolerance
Neuroscience Bulletin (2023)
-
Oxycodone withdrawal induces HDAC1/HDAC2-dependent transcriptional maladaptations in the reward pathway in a mouse model of peripheral nerve injury
Nature Neuroscience (2023)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.